openPR Logo
Press release

Recombinant Human Endostatin Market: Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co

04-01-2019 03:43 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Recombinant Human Endostatin

Recombinant Human Endostatin

Increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market. For instance, according to a paper published in the journal Nature, September 2015, a study was conducted to evaluate effects of recombinant human endostatin in combination with radiotherapy for treating esophageal squamous cell carcinoma and to discover its potential mechanisms. These findings suggested that recombinant human endostatin is a potential anti-angiogenic agent in esophageal squamous cell carcinoma mainly when combined with radiotherapy.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2262

Furthermore, according to National Center for Biotechnology Information (NCBI) January 2017, recombinant human endostatin in combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) may aid in treatment of Angioimmunoblastic T Cell Lymphoma (AITL), a form of Peripheral T Cell Lymphoma (PTCL). Such novel therapies for PTCL treatment are immediately desired to improve the outcomes of patients with this disease. These factors are expected to propel growth of the recombinant human endostatin market.

Endostatin is a protein located in most Basement Membranes (BMs) in the body such as vascular basement membranes. A number of clinical studies have validated the significant survival benefits of recombinant human endostatin in treating late stage Non-Small-Cell Lung Carcinoma (NSCLC). Therefore, recombinant human endostatin (Endostar) was approved by the State Food and Drug Administration of China (CFDA) in September 2005, for the treatment of NSCLC. Endostatin is expressed in various organs, with the highest levels in liver, lung, and kidney.

Market Drivers

Government initiatives to reduce prices of anticancer drugs is expected to drive growth of the recombinant human endostatin market during the forecast period. For instance, in August 2018, Government of China took initiatives to reduce prices of anticancer drugs by 44%. Chinese National Health and Family Planning Commission organized a national-wide drug price and reimbursement drug list negotiation, in which a total of 39 products have been successfully added including recombinant human endostatin.

Market Restraint

Increasing challenges in significant production of recombinant human endostatin is expected to hinder the market growth. For instance, in April 2017, according to a National Center for Biotechnology Information (NCBI) report, tumor treatment needs large quantities of biologically active recombinant human endostatin, which in turn requires production of large quantities of recombinant human endostatin. This process is difficult as it based on recombinant DNA technology and also have low success rates for the treatment of cancer. Furthermore, the cost of recombinant human endostatin is high and it has short half-life. Endostatin is unstable since, endostatin-purification process may denature its structure and the resultant yields may be low.

The major players operating in the recombinant human endostatin market include;
* Pfizer Inc.,
* Novus Biologicals.
* Biocon.
* Novartis AG.
* Thermo Fisher Scientific.
* Yantai Medgenn Ltd.
* FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
* PeproTech, Inc.
* Onyx Pharmaceuticals, Inc.
* Genexine, Inc., Hetero.
* Intas Pharmaceuticals Ltd.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2262

Market – Taxonomy

By Application
Medical Application
Scientific Application

By Region
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recombinant Human Endostatin Market: Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co here

News-ID: 1681722 • Views: 1064

More Releases from Coherent Market Insights

Europe E-bike Market will be Worth of US$ 13,636 Mn by 2030 | Accell Group, Bion …
The latest report by Coherent Market Insights, titled "Europe E-bike Market Trends, Types, Report and Forecast 2022-2030," provides a detailed analysis of the market, evaluating it based on sales revenue, growth strategies, sales pattern, production, consumption, and supply-demand analysis of the industry with recent developments. The research explores the effects of the most recent market developments on the overall industry. Along with analysing the market using the SWOT and Porter's
Electric Power Steering (EPS) System Market 2022: Industry Outlook, Demand Forec …
The latest report by Coherent Market Insights, titled "Global Electric Power Steering (EPS) System Market Trends, Types, Report and Forecast 2022-2030," provides a detailed analysis of the market, evaluating it based on sales revenue, growth strategies, sales pattern, production, consumption, and supply-demand analysis of the industry with recent developments. The research explores the effects of the most recent market developments on the overall industry. Along with analysing the market using
Global and Japan Document Scanning Services Market to Witness Rapid Growth in De …
The latest report by Coherent Market Insights, titled "Global and Japan Document Scanning Services Market Trends, Types, Report and Forecast 2022-2028," provides a detailed analysis of the market, evaluating it based on sales revenue, growth strategies, sales pattern, production, consumption, and supply-demand analysis of the industry with recent developments. The research explores the effects of the most recent market developments on the overall industry. Along with analysing the market using
Acrylic Paints Market Size Forecast 2022-2028 by Regions, Leading Key Players, G …
New Research Study Acrylic Paints Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share, and Outlook has been added to Coherent Market insight. The report includes Porter's Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable

All 5 Releases